Abstract
Acinetobacter baumannii one of the important multidrug-resistant (MDR) opportunistic nosocomial pathogens, in part due to its high capacity of acquiring resistance to diverse antibiotic groups. Twenty five Clinical sample samples were gathered from various sources from Baquba Teaching Hospital, from the period june2022 to October 2022 after consulting with the expert doctor, from both in- and out-patients, and the samples were sent to the lab. Each sample's data was entered onto a unique form, and they included: 10 (sputum samples from respiratory tract infections; 5 burn samples; 4 wound samples; 6 samples for urinary tract infections. After being cultured on MacConkey agar and Blood agar, the isolates were identified. Oxidase and Catalase biochemical tests were performed on the samples, and Vitik2 was employed to make the final diagnosis. Twelve isolates of Acinetobacter baumannii were found after culture and identification; of these, five were found in sputum, two in burns, two in urinary tract infections, and three in wounds. Results of 10 different antibiotics' sensitivity tests on A. baumannii isolates from various clinical sources at the Baquba Teaching Hospital showed that the bacterium showed varying degrees of resistance to the medications.. 100% of the samples displayed resistance to Cefoxitin, Oxacillin, Ceftazidim, Cefepime, and Tetracyclin, while 75% displayed excellent susceptibility to Imipenem, The resistance patterns of isolates were also determined isolates showed to quinolone antibiotic such as Levofloxacin 6/12( 50%), Norfloxacin 7/12 (58.33%) , Ofloxacin 6/12( 50%) ,Ciprofloxacin 3 /12(25%).
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call